Sign In
Buy VRAX
$4.07
-0.0100 (-0.245%)
At Close: Jul 13, 2026
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
04:05pm, Friday, 10'th Jul 2026
LONDON, July 10, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) today closed its previously announced exercise of certain outstanding preferred investment
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
01:35pm, Thursday, 09'th Jul 2026
LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of
Why this biotech stock more than tripled on Thursday
12:33pm, Thursday, 09'th Jul 2026
Virax Biolabs (VRAX) shares exploded higher on Thursday morning after management announced a lucrative cross-border commercial breakthrough. In a press release dated July 9th, the company said its UK
Why Did Virax Biolabs Stock Triple In One Session?
10:31am, Thursday, 09'th Jul 2026
Virax Biolabs Group Limited (NASDAQ:VRAX) stock is up during Thursday's premarket session, as the company has signed a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSe
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
07:30am, Thursday, 09'th Jul 2026
LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered int
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
09:00am, Wednesday, 24'th Jun 2026
LONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that the board of directors of the Company approved a share consolidation of
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
07:30am, Tuesday, 26'th May 2026
LONDON, May 26, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
07:34am, Tuesday, 14'th Apr 2026
Virax Biolabs is advancing a focused strategy centered on ViraxImmune™ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite i
What's Behind The Jump In Virax Biolabs Stock?
10:38am, Tuesday, 31'st Mar 2026
Virax Biolabs said that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
07:34am, Tuesday, 31'st Mar 2026
LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update
02:55am, Wednesday, 11'th Mar 2026
Virax Biolabs Group Limited (NASDAQ: VRAX - Get Free Report) was the target of a significant growth in short interest in February. As of February 27th, there was short interest totaling 55,704 shares,
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 67.6% in February
03:22am, Thursday, 26'th Feb 2026
Virax Biolabs Group Limited (NASDAQ: VRAX - Get Free Report) saw a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 21,126 shares, a drop o
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 5.3% – Here’s What Happened
04:13am, Saturday, 21'st Feb 2026
Virax Biolabs Group Limited (NASDAQ: VRAX - Get Free Report)'s stock price dropped 5.3% on Friday. The company traded as low as $0.21 and last traded at $0.2130. Approximately 93,300 shares were trade
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why
01:01pm, Thursday, 15'th Jan 2026
Virax Biolabs Group Limited (VRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Head-To-Head Contrast: MannKind (NASDAQ:MNKD) and Virax Biolabs Group (NASDAQ:VRAX)
03:30am, Monday, 08'th Dec 2025
Virax Biolabs Group (NASDAQ: VRAX - Get Free Report) and MannKind (NASDAQ: MNKD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two bus
